Showing results (21-30 of 59) with videos related to

Sort By:
Pageof 6
Contemporary Clinical Trials|May 3, 2026
Hybrid-delivered cognitive behavioral symptom management and activity coaching intervention for patients following hematopoietic stem cell transplant or CAR T-cell therapy: Protocol of a randomized controlled trialPatricia B Pedreira, Tamara J Somers, Hannah M Fisher, et al.
Research and Practice in Thrombosis and Haemostasis|May 31, 2024
An epidemiologic study comparing cancer- and noncancer-associated venous thromboembolism in a racially diverse Southeastern United States countyAndrew M Peseski, Sargam Kapoor, Maragatha Kuchibhatla, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical PracticeLindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
Leukemia & Lymphoma|July 19, 2013
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studiesDaphne R Friedman, Mark C Lanasa, Patricia H Davis, et al.
JACC. Cardiooncology|July 12, 2022
Cardiometabolic Comorbidities in Cancer Survivors: <i>JACC: CardioOncology</i> State-of-the-Art ReviewLeah L Zullig, Anthony D Sung, Michel G Khouri, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 9, 2020
Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results From the informCLL RegistryAnthony R Mato, Jacqueline C Barrientos, Nilanjan Ghosh, et al.
Journal of Medical Education and Curricular Development|August 6, 2024
Educating Hematology-Oncology Fellows About How to Communicate with Patients About Clinical Trials: A Needs AssessmentNaomi D Parker, Martina C Murphy, Susan Eggly, et al.
Blood Advances|May 19, 2019
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLLAnthony R Mato, Lindsey E Roeker, Toby A Eyre, et al.
Blood|June 11, 2021
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapyShuo Ma, John F Seymour, Danielle M Brander, et al.
The Lancet. Oncology|February 25, 2018
Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human studyHoward A Burris, Ian W Flinn, Manish R Patel, et al.
Pageof 6